Home>Investors Investors Latest Announcements Unaudited Financial Results (Standalone And Consolidated) For The First Quarter Ended 30th June, 2025 14 AUG 2025 | READ MORE Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 06 AUG 2025 | READ MORE Result of Postal Ballot by remote e-voting & Scrutinizer's Report 01 AUG 2025 | READ MORE Newspaper Advertisement – Postal Ballot Notice 02 JULY 2025 | READ MORE Notice of Postal Ballot - Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 01 JULY 2025 | READ MORE Intimation under Regulation 30(5) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 01 JULY 2025 | READ MORE Incorporation of Glenmark Consumer Care Limited 23 MAY 2025 | READ MORE Audited Financial Results and Recommendation of Final Dividend 23 MAY 2025 | READ MORE Grant of ESOPs 22 MAY 2025 | READ MORE Board Meeting Intimation – 23 May 2025 23 MAY 2025 | READ MORE Result of Postal Ballot by remote e-voting & Scrutinizer's Report 28 APR 2025 | READ MORE Glenmark Pharmaceuticals Inc., USA to launch Mixed Amphetamines Immediate-Release Tablets 16 APR 2025 | READ MORE Appointment of Senior Management Personnel of the Company 07 APR 2025 | READ MORE Glenmark Pharmaceuticals Inc., USA launches Vancomycin Hydrochloride for Injection USP, 750 mg/vial, 1.25 g/vial and 1.5 g/vial (Single-Dose Vial) 01 APR 2025 | READ MORE Newspaper Advertisement – Postal Ballot Notice 27 MAR 2025 | READ MORE Notice of Postal Ballot - Disclosure under Regulation 30 of the SEBI LODR Regulations, 2015 26 MAR 2025 | READ MORE Glenmark Pharmaceuticals Launches Pioneering Nutrition Program to Fight Malnutrition in the Philippines 25 MAR 2025 | READ MORE Glenmark receives ANDA approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC) 20 MAR 2025 | READ MORE Glenmark Pharma Expands Cardiometabolic Portfolio with the Launch of Empagliflozin and its Fixed-Drug Combinations in India 12 MAR 2025 | READ MORE Glenmark Therapeutics Inc., USA launches Polyethylene Glycol 3350, Powder for Solution, 17 grams/capful (OTC) 10 MAR 2025 | READ MORE Glenmark Pharmaceuticals Inc., USA launches acquires and launches Acetylcysteine Injection 6 gm-30 mL (200 mg-mL) Single-Dose Vials 03 MAR 2025 | READ MORE Glenmark Pharmaceuticals Inc., USA launches Epinephrine Injection USP, 10 mg/10 mL (1 mg/mL) Multiple-Dose Vial 27 FEB 2025 | READ MORE Q3 FY 2025 Results - Newspaper Advertisement 17 FEB 2025 | READ MORE Press Release and Management Discussion & Analysis 14 FEB 2025 | READ MORE Outcome of the Board Meeting – Change in Directorate 14 FEB 2025 | READ MORE U.S. FDA inspection at the Company's Facility at Indore, Madhya Pradesh, India 14 FEB 2025 | READ MORE Glenmark Pharma reports consolidated revenue growth of 35.1%, EBITDA margin of 17.7% and PAT margin of 10.3% YoY for Q3 FY2025 14 FEB 2025 | READ MORE Unaudited Financial Results (Standalone and Consolidated) for the Third Quarter and Nine Months ended 31st December, 2024 14 FEB 2025 | READ MORE Glenmark Pharmaceuticals Inc., USA launches Latanoprost Ophthalmic Solution 0.005% 14 FEB 2025 | READ MORE Glenmark Pharmaceuticals Inc., USA launches Clindamycin Phosphate Foam, 1% 12 FEB 2025 | READ MORE Intimation under Regulation 30 of SEBI LODR 08 FEB 2025 | READ MORE Q3 FY 25 Earnings Call Invitation – 17 February 2025 05 FEB 2025 | READ MORE Board Meeting Intimation – 14 February 2025 03 FEB 2025 | READ MORE Glenmark Pharmaceuticals Inc., USA launches Phytonadione Injectable Emulsion USP, 10 mg/mL Single Dose Ampules 21 JAN 2025 | READ MORE Intimation of change in the name of the Step Down Wholly Owned Subsidiaries of the Company 08 JAN 2025 | READ MORE Year – 2025 Year – 2024 Year – 2023 Year – 2022 Year – 2021 Year – 2020 Year – 2019 Year – 2018 Year – 2017 Year – 2016 SHAREHOLDERS CORNERBe a part of the new world KNOW MORE GOVERNANCEThe principles that govern us KNOW MORE REPORTS AND PRESENTATIONPerformance in numbers KNOW MORE About Us Leading, integrated, global, research-led organization. Words which define us and our vision to discover a healthier future KNOW MORE
